Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. [Review]

MedStar author(s):
Citation: Current Opinion in Infectious Diseases. 35(6):589-594, 2022 Dec 01.PMID: 36206150Institution: MedStar Washington Hospital Center | MedStar Washington Hospital CenterDepartment: Internal Medicine Residency | Medicine/Pulmonary-Critical Care | Pulmonary/Critical Care FellowshipForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Gram-Negative Bacterial Infections | *Urinary Tract Infections | Anti-Bacterial Agents/pd [Pharmacology] | Anti-Bacterial Agents/tu [Therapeutic Use] | Cefepime/pd [Pharmacology] | Cefepime/tu [Therapeutic Use] | Drug Resistance, Multiple, Bacterial | Gram-Negative Bacterial Infections/dt [Drug Therapy] | Gram-Negative Bacterial Infections/mi [Microbiology] | Humans | Microbial Sensitivity Tests | Sulbactam/pd [Pharmacology] | Sulbactam/tu [Therapeutic Use] | Urinary Tract Infections/dt [Drug Therapy]Year: 2022Local holdings: Available online from MWHC library: 1998 - presentISSN:
  • 0951-7375
Name of journal: Current opinion in infectious diseasesAbstract: PURPOSE OF REVIEW: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections.RECENT FINDINGS: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii . Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. Finally, xeruborbactam is an ultrabroad beta-lactamase inhibitor that can be paired with a range of intravenous and oral agents. It exhibits enhanced in-vitro activity against many MDR pathogens, including those resistant to newer, broader spectrum options. Data in humans with xeruborbactam are limited.SUMMARY: Each of the newer options reviewed possesses a unique range of in-vitro activity against select, challenging pathogens with some narrowly tailored and other broader in activity. Several have both oral and intravenous formulations. Two agents have presented data from recent phase III trials, whereas two are not as advanced in their clinical programs. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.All authors: Arya R, Goldner BS, Shorr AFFiscal year: FY2023Digital Object Identifier: Date added to catalog: 2022-12-13
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 36206150 Available 36206150

Available online from MWHC library: 1998 - present

PURPOSE OF REVIEW: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections.

RECENT FINDINGS: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime-taniborbactam, and xeruborbactam). Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii . Cefepime-taniborbactam possesses in-vitro potency against a range of troubling pathogens and we await further information on a recently completed study on complicated urinary tract infection. Finally, xeruborbactam is an ultrabroad beta-lactamase inhibitor that can be paired with a range of intravenous and oral agents. It exhibits enhanced in-vitro activity against many MDR pathogens, including those resistant to newer, broader spectrum options. Data in humans with xeruborbactam are limited.

SUMMARY: Each of the newer options reviewed possesses a unique range of in-vitro activity against select, challenging pathogens with some narrowly tailored and other broader in activity. Several have both oral and intravenous formulations. Two agents have presented data from recent phase III trials, whereas two are not as advanced in their clinical programs. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

English

Powered by Koha